Kenneth D. Miller - Publications

Affiliations: 
Columbia University, New York, NY 
Area:
Computation & Theory
Website:
http://neurotheory.columbia.edu/~ken/

224 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Hennequin G, Ahmadian Y, Rubin DB, Lengyel M, Miller KD. The Dynamical Regime of Sensory Cortex: Stable Dynamics around a Single Stimulus-Tuned Attractor Account for Patterns of Noise Variability. Neuron. 98: 846-860.e5. PMID 29772203 DOI: 10.1016/j.neuron.2018.04.017  1
2016 Miller KD. Canonical computations of cerebral cortex. Current Opinion in Neurobiology. 37: 75-84. PMID 26868041 DOI: 10.1016/j.conb.2016.01.008  1
2016 Miller KD, Martignoni D. Organizational learning with forgetting: Reconsidering the exploration–exploitation tradeoff Strategic Organization. 14: 53-72. DOI: 10.1177/1476127015608337  0.32
2016 Murphy BK, Miller KD. Balanced Amplification: A New Mechanism of Selective Amplification of Neural Activity Patterns. Neuron 61, 635-648; February 26, 2009 Neuron. 89: 235. DOI: 10.1016/j.neuron.2015.12.010  1
2015 Aggarwal H, Callahan CM, Miller KD, Tu W, Loehrer PJ. Are There Differences in Treatment and Survival Between Poor, Older Black and White Women with Breast Cancer? Journal of the American Geriatrics Society. 63: 2008-13. PMID 26456765 DOI: 10.1111/jgs.13669  0.36
2015 Schneider BP, Li L, Radovich M, Shen F, Miller C, Flockhart DA, Jiang G, Vance GH, Gardner L, Vatta M, Bai C, Lai D, Koller D, Zhao F, O'Neill A, et al. Genome-wide association studies for taxane-induced peripheral neuropathy (TIPN) in ECOG-5103 and ECOG-1199. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26138065 DOI: 10.1158/1078-0432.CCR-15-0586  0.36
2015 Partridge AH, Sepucha K, O'Neill A, Miller KD, Motley C, Swaby RF, Schneider BP, Dang CT, Northfelt DW, Sledge GW. Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer. Jama Oncology. 1: 369-74. PMID 26114161 DOI: 10.1001/jamaoncol.2015.0246  0.32
2015 Ahmadian Y, Fumarola F, Miller KD. Properties of networks with partially structured and partially random connectivity. Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics. 91: 012820. PMID 25679669  1
2015 Ziskind AJ, Emondi AA, Kurgansky AV, Rebrik SP, Miller KD. Neurons in cat V1 show significant clustering by degree of tuning. Journal of Neurophysiology. 113: 2555-81. PMID 25652921 DOI: 10.1152/jn.00646.2014  0.8
2015 Rubin DB, Van Hooser SD, Miller KD. The stabilized supralinear network: a unifying circuit motif underlying multi-input integration in sensory cortex. Neuron. 85: 402-17. PMID 25611511 DOI: 10.1016/j.neuron.2014.12.026  1
2015 Hærem T, Pentland BT, Miller KD. Task complexity: Extending a core concept Academy of Management Review. 40: 446-460. DOI: 10.5465/amr.2013.0350  0.32
2015 Miller KD. Organizational Research as Practical Theology Organizational Research Methods. 18: 276-299. DOI: 10.1177/1094428114559216  0.32
2015 Miller KD. Agent-Based Modeling and Organization Studies: A critical realist perspective Organization Studies. 36: 175-196. DOI: 10.1177/0170840614556921  0.32
2015 Ahmadian Y, Fumarola F, Miller KD. Properties of networks with partially structured and partially random connectivity Physical Review E - Statistical, Nonlinear, and Soft Matter Physics. 91. DOI: 10.1103/PhysRevE.91.012820  1
2015 Perkins SM, Bales C, Vladislav T, Althouse S, Miller KD, Sandusky G, Badve S, Nakshatri H. TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis Breast Cancer Research and Treatment. 152: 519-531. DOI: 10.1007/s10549-015-3492-2  0.36
2015 Miller KD, Lin SJ. Analogical reasoning for diagnosing strategic issues in dynamic and complex environments Strategic Management Journal. 36: 2000-2020. DOI: 10.1002/smj.2335  0.32
2014 Toyoizumi T, Kaneko M, Stryker MP, Miller KD. Modeling the dynamic interaction of Hebbian and homeostatic plasticity. Neuron. 84: 497-510. PMID 25374364 DOI: 10.1016/j.neuron.2014.09.036  1
2014 O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3840-7. PMID 25349301 DOI: 10.1200/JCO.2014.55.2984  0.36
2014 Miller KD, Althouse SK, Nabell L, Rugo H, Carey L, Kimmick G, Jones DR, Merino MJ, Steeg PS. A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. Breast Cancer Research and Treatment. 148: 99-106. PMID 25257727 DOI: 10.1007/s10549-014-3131-3  0.36
2014 Cimenser A, Miller KD. The effects of short-term synaptic depression at thalamocortical synapses on orientation tuning in cat V1. Plos One. 9: e106046. PMID 25157879 DOI: 10.1371/journal.pone.0106046  1
2014 Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, et al. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. British Journal of Cancer. 111: 1241-8. PMID 25117820 DOI: 10.1038/bjc.2014.430  0.36
2014 Champion VL, Wagner LI, Monahan PO, Daggy J, Smith L, Cohee A, Ziner KW, Haase JE, Miller KD, Pradhan K, Unverzagt FW, Cella D, Ansari B, Sledge GW. Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall quality of life domains. Cancer. 120: 2237-46. PMID 24891116 DOI: 10.1002/cncr.28737  0.36
2014 Ramirez A, Pnevmatikakis EA, Merel J, Paninski L, Miller KD, Bruno RM. Spatiotemporal receptive fields of barrel cortex revealed by reverse correlation of synaptic input. Nature Neuroscience. 17: 866-75. PMID 24836076 DOI: 10.1038/nn.3720  1
2014 Miller KD, Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, Albain KS, Crivellari D, Fang L, Michelson G, de Haas SL, Burris HA. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1437-44. PMID 24733796 DOI: 10.1200/JCO.2013.52.6590  0.36
2014 Ruddy KJ, O'Neill A, Miller KD, Schneider BP, Baker E, Sparano JA, Dang C, Northfelt DW, Sledge GW, Partridge AH. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Research and Treatment. 144: 591-7. PMID 24584876 DOI: 10.1007/s10549-014-2891-0  0.36
2014 Miller KD, Choi S, Pentland BT. The role of transactive memory in the formation of organizational routines Strategic Organization. 12: 109-133. DOI: 10.1177/1476127014521609  0.32
2013 Toyoizumi T, Miyamoto H, Yazaki-Sugiyama Y, Atapour N, Hensch TK, Miller KD. A theory of the transition to critical period plasticity: inhibition selectively suppresses spontaneous activity. Neuron. 80: 51-63. PMID 24094102 DOI: 10.1016/j.neuron.2013.07.022  1
2013 Mina LA, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Investigational New Drugs. 31: 1307-10. PMID 23812905 DOI: 10.1007/s10637-013-9976-1  0.36
2013 Gao M, Wang M, Miller KD, Zheng QH. Synthesis of (Z)-2-((1H-indazol-3-yl)methylene)-6-[¹¹C]methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one as a new potential PET probe for imaging of the enzyme PIM1. Bioorganic & Medicinal Chemistry Letters. 23: 4342-6. PMID 23791570 DOI: 10.1016/j.bmcl.2013.05.091  0.36
2013 Ahmadian Y, Rubin DB, Miller KD. Analysis of the stabilized supralinear network. Neural Computation. 25: 1994-2037. PMID 23663149 DOI: 10.1162/NECO_a_00472  1
2013 Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2128-35. PMID 23650416 DOI: 10.1200/JCO.2012.43.7251  0.36
2013 Gao M, Yang Q, Wang M, Miller KD, Sledge GW, Zheng QH. Synthesis of radiolabeled protein disulfide isomerase (PDI) inhibitors as new potential PET agents for imaging of the enzyme PDI in neurological disorders and cancer. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 74: 61-9. PMID 23376309 DOI: 10.1016/j.apradiso.2013.01.003  0.36
2013 Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, et al. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1281-9. PMID 23340303 DOI: 10.1158/1078-0432.CCR-12-3029  0.36
2013 Wang M, Gao M, Miller KD, Zheng QH. Synthesis of 2,6-difluoro-N-(3-[11C]methoxy-1H-pyrazolo[3,4-b]pyridine-5-yl)-3-(propylsulfonamidio)benzamide as a new potential PET agent for imaging of B-Raf(V600E) in cancers. Bioorganic & Medicinal Chemistry Letters. 23: 1017-21. PMID 23294704 DOI: 10.1016/j.bmcl.2012.12.027  0.36
2013 Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 119: 1140-8. PMID 23065954 DOI: 10.1002/cncr.27819  0.36
2012 Schneider BP, Shen F, Miller KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. The Lancet. Oncology. 13: e427-36. PMID 23026828 DOI: 10.1016/S1470-2045(12)70275-9  0.36
2012 Bigatti SM, Steiner JL, Miller KD. Cognitive appraisals, coping and depressive symptoms in breast cancer patients. Stress and Health : Journal of the International Society For the Investigation of Stress. 28: 355-61. PMID 22888085 DOI: 10.1002/smi.2444  0.36
2012 Gao M, Wang M, Miller KD, Zheng QH. Simple synthesis of carbon-11-labeled chromen-4-one derivatives as new potential PET agents for imaging of DNA-dependent protein kinase (DNA-PK) in cancer. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 70: 1558-63. PMID 22732390 DOI: 10.1016/j.apradiso.2012.04.023  0.36
2012 Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3234-41. PMID 22649126 DOI: 10.1200/JCO.2011.40.5902  0.36
2012 Ziner KW, Sledge GW, Bell CJ, Johns S, Miller KD, Champion VL. Predicting fear of breast cancer recurrence and self-efficacy in survivors by age at diagnosis. Oncology Nursing Forum. 39: 287-95. PMID 22543387 DOI: 10.1188/12.ONF.287-295  0.36
2012 Wang M, Xu L, Gao M, Miller KD, Sledge GW, Zheng QH. Synthesis of 2-[11C]methoxy-3,17β-O,O-bis(sulfamoyl)estradiol as a new potential PET agent for imaging of steroid sulfatase (STS) in cancers. Steroids. 77: 864-70. PMID 22542502 DOI: 10.1016/j.steroids.2012.04.007  0.36
2012 Decker CL, Pais S, Miller KD, Goulet R, Fifea BL. A brief intervention to minimize psychosexual morbidity in dyads coping with breast cancer. Oncology Nursing Forum. 39: 176-85. PMID 22374491 DOI: 10.1188/12.ONF.176-185  0.36
2012 Wang M, Gao M, Miller KD, Sledge GW, Zheng QH. [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers. Bioorganic & Medicinal Chemistry Letters. 22: 1569-74. PMID 22297110 DOI: 10.1016/j.bmcl.2011.12.136  0.36
2012 Von Ah DM, Russell KM, Carpenter J, Monahan PO, Qianqian Z, Tallman E, Ziner KW, Storniolo AM, Miller KD, Giesler RB, Haase J, Otte J, Champion VL. Health-related quality of life of african american breast cancer survivors compared with healthy African American women. Cancer Nursing. 35: 337-46. PMID 22228394 DOI: 10.1097/NCC.0b013e3182393de3  0.36
2012 Miller KD, Fumarola F. Mathematical equivalence of two common forms of firing rate models of neural networks. Neural Computation. 24: 25-31. PMID 22023194 DOI: 10.1162/NECO_a_00221  1
2012 Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW. A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 331-7. PMID 21821545 DOI: 10.1093/annonc/mdr344  0.36
2012 Miller KD, Pentland BT, Choi S. Dynamics of Performing and Remembering Organizational Routines Journal of Management Studies. 49: 1536-1558. DOI: 10.1111/j.1467-6486.2012.01062.x  0.32
2012 Randall NM, Miller KD, Sledge GW. Male Breast Cancer Textbook of Uncommon Cancer. 233-241. DOI: 10.1002/9781118464557.ch16  0.36
2011 Gao M, Wang M, Miller KD, Zheng QH. Facile radiosynthesis of new carbon-11-labeled propanamide derivatives as selective androgen receptor modulator (SARM) radioligands for prostate cancer imaging. Steroids. 76: 1505-12. PMID 21867721 DOI: 10.1016/j.steroids.2011.08.005  0.36
2011 Wessels AM, Flockhart DA, Carpenter JS, Radovich M, Li L, Miller KD, Sledge GW, Storniolo AM, Otte JL, Lemler SM, Schneider BP. Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide. The Breast Journal. 17: 536-8. PMID 21827565 DOI: 10.1111/j.1524-4741.2011.01144.x  0.36
2011 Wang M, Gao M, Miller KD, Zheng QH. Synthesis of [¹¹C]PBR06 and [¹⁸F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO). Steroids. 76: 1331-40. PMID 21756927 DOI: 10.1016/j.steroids.2011.06.012  0.36
2011 Gao M, Wang M, Miller KD, Zheng QH. Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer. European Journal of Medicinal Chemistry. 46: 4760-7. PMID 21640445 DOI: 10.1016/j.ejmech.2011.05.024  0.36
2011 Gao M, Lola CM, Wang M, Miller KD, Sledge GW, Zheng QH. Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer. Bioorganic & Medicinal Chemistry Letters. 21: 3222-6. PMID 21549594 DOI: 10.1016/j.bmcl.2011.04.049  0.36
2011 Bigatti SM, Brown LF, Steiner JL, Miller KD. Breast cancer in a wife: how husbands cope and how well it works. Cancer Nursing. 34: 193-201. PMID 21522059 DOI: 10.1097/NCC.0b013e3181ef094c  0.36
2011 Wang M, Xu L, Gao M, Miller KD, Sledge GW, Zheng QH. [11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C. Bioorganic & Medicinal Chemistry Letters. 21: 1649-53. PMID 21320780 DOI: 10.1016/j.bmcl.2011.01.100  0.36
2011 Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 372-81. PMID 21224365 DOI: 10.1158/1078-0432.CCR-10-1791  0.36
2011 Wang M, Gao M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3). Bioorganic & Medicinal Chemistry Letters. 21: 245-9. PMID 21115250 DOI: 10.1016/j.bmcl.2010.11.026  0.36
2011 Stantz KM, Cao M, Cao N, Liang Y, Miller KD. Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 13: 1183-95. PMID 20957443 DOI: 10.1007/s11307-010-0441-7  0.36
2011 Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Research and Treatment. 127: 375-84. PMID 20602165 DOI: 10.1007/s10549-010-1004-y  0.36
2011 Bigatti SM, Wagner CD, Lydon-Lam JR, Steiner JL, Miller KD. Depression in husbands of breast cancer patients: relationships to coping and social support. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 19: 455-66. PMID 20217149 DOI: 10.1007/s00520-010-0835-8  0.36
2011 Wang M, Gao M, Miller KD, Zheng QH. Synthesis of a new carbon-11-labeled sulfamate derivative as a potential PET tracer for imaging of breast cancer aromatase and steroid sulfatase expression Synthetic Communications. 41: 1127-1140. DOI: 10.1080/00397911003797825  0.36
2011 Miller KD, Tsang EWK. Testing management theories: Critical realist philosophy and research methods Strategic Management Journal. 32: 139-158. DOI: 10.1002/smj.868  0.32
2011 Pitkow X, Ahmadian Y, Miller KD. Learning unbelievable probabilities Advances in Neural Information Processing Systems 24: 25th Annual Conference On Neural Information Processing Systems 2011, Nips 2011 1
2010 Miller KD. Neuroscience. Ï€ = visual cortex. Science (New York, N.Y.). 330: 1059-60. PMID 21097928 DOI: 10.1126/science.1198857  1
2010 Wang M, Gao M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent. Nuclear Medicine and Biology. 37: 763-75. PMID 20870151 DOI: 10.1016/j.nucmedbio.2010.04.186  0.36
2010 Wang M, Gao M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Synthesis of carbon-11-labeled casimiroin analogues as new potential PET agents for imaging of quinone reductase 2 and aromatase expression in breast cancer. Steroids. 75: 967-73. PMID 20558190 DOI: 10.1016/j.steroids.2010.06.004  0.36
2010 Gao M, Lola CM, Wang M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Synthesis of carbon-11-labeled tricyclic necroptosis inhibitors as new potential PET agents for imaging of tumor necrosis factor alpha (TNF-alpha). Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 68: 1950-8. PMID 20472449 DOI: 10.1016/j.apradiso.2010.04.030  0.36
2010 Gao M, Wang M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Facile synthesis of carbon-11-labeled cholesterol-based cationic lipids as new potential PET probes for imaging of gene delivery in cancer. Steroids. 75: 715-20. PMID 20451540 DOI: 10.1016/j.steroids.2010.04.009  0.36
2010 Gao M, Wang M, Miller KD, Hutchins GD, Zheng QH. Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging. Bioorganic & Medicinal Chemistry. 18: 2099-106. PMID 20189815 DOI: 10.1016/j.bmc.2010.02.011  0.36
2010 Wang M, Zheng DX, Luo MB, Gao M, Miller KD, Hutchins GD, Zheng QH. Synthesis of carbon-11-labeled tariquidar derivatives as new PET agents for imaging of breast cancer resistance protein (ABCG2). Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 68: 1098-103. PMID 20181488 DOI: 10.1016/j.apradiso.2010.02.008  0.36
2010 Gao M, Wang M, Miller KD, Hutchins GD, Zheng QH. Synthesis of carbon-11-labeled 4-aryl-4H-chromens as new PET agents for imaging of apoptosis in cancer. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 68: 110-6. PMID 19818636 DOI: 10.1016/j.apradiso.2009.09.067  0.36
2010 Miller KD, Lin SJ. Different truths in different worlds Organization Science. 21: 97-114. DOI: 10.1287/orsc.1080.0409  0.32
2010 Stantz KM, Cao M, Liu B, Miller KD, Guo L. Molecular imaging of neutropilin-1 receptor using photoacoustic spectroscopy in breast tumors Progress in Biomedical Optics and Imaging - Proceedings of Spie. 7564. DOI: 10.1117/12.842271  0.36
2010 Wang M, Gao M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Radiosynthesis of new carbon-11-labeled nimesulide analogs as potential PET SAER tracers for imaging of aromatase expression in breast cancer Synthetic Communications. 40: 749-758. DOI: 10.1080/00397910903013747  0.36
2009 Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5297-302. PMID 19706811 DOI: 10.1158/1078-0432.CCR-08-2576  0.36
2009 Gao M, Wang M, Miller KD, Hutchins GD, Zheng QH. Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of inflammation. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 67: 2019-24. PMID 19683453 DOI: 10.1016/j.apradiso.2009.07.022  0.36
2009 Wang M, Mickens J, Gao M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer. Steroids. 74: 896-905. PMID 19559719 DOI: 10.1016/j.steroids.2009.06.006  0.36
2009 Ozeki H, Finn IM, Schaffer ES, Miller KD, Ferster D. Inhibitory stabilization of the cortical network underlies visual surround suppression. Neuron. 62: 578-92. PMID 19477158 DOI: 10.1016/j.neuron.2009.03.028  1
2009 Toyoizumi T, Miller KD. Equalization of ocular dominance columns induced by an activity-dependent learning rule and the maturation of inhibition. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 6514-25. PMID 19458222 DOI: 10.1523/JNEUROSCI.0492-08.2009  1
2009 Escola S, Eisele M, Miller K, Paninski L. Maximally reliable Markov chains under energy constraints. Neural Computation. 21: 1863-912. PMID 19292647 DOI: 10.1162/neco.2009.08-08-843  1
2009 Murphy BK, Miller KD. Balanced amplification: a new mechanism of selective amplification of neural activity patterns. Neuron. 61: 635-48. PMID 19249282 DOI: 10.1016/j.neuron.2009.02.005  1
2009 Mina L, Krop I, Zon RT, Isakoff SJ, Schneider CJ, Yu M, Johnson C, Vaughn LG, Wang Y, Hristova-Kazmierski M, Shonukan OO, Sledge GW, Miller KD. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Investigational New Drugs. 27: 565-70. PMID 19214387 DOI: 10.1007/s10637-009-9220-1  0.36
2009 Cao M, Liang Y, Shen C, Miller KD, Stantz KM. Developing DCE-CT to quantify intra-tumor heterogeneity in breast tumors with differing angiogenic phenotype. Ieee Transactions On Medical Imaging. 28: 861-71. PMID 19150783 DOI: 10.1109/TMI.2008.2012035  0.36
2009 Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment. 115: 115-21. PMID 18496750 DOI: 10.1007/s10549-008-0055-9  0.36
2009 Wang M, Gao M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Simple synthesis of carbon-11 labeled styryl dyes as new potential PET RNA-specific, living cell imaging probes. European Journal of Medicinal Chemistry. 44: 2300-6. PMID 18396357 DOI: 10.1016/j.ejmech.2008.02.033  0.36
2009 Miller KD. Organizational risk after modernism Organization Studies. 30: 157-180. DOI: 10.1177/0170840608101475  0.32
2009 Miller KD, Fabian F, Lin SJ. Strategies for online communities Strategic Management Journal. 30: 305-322. DOI: 10.1002/smj.735  0.32
2008 Ademuyiwa FO, Miller KD. Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer. Clinical Breast Cancer. 8: S151-6. PMID 19158035 DOI: 10.3816/CBC.2008.s.011  0.36
2008 Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, ... Miller KD, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4672-8. PMID 18824714 DOI: 10.1200/JCO.2008.16.1612  0.36
2008 Gokmen-Polar Y, Miller KD. Redefining the target again: chemotherapeutics as vascular disrupting agents? Cancer Cell. 14: 195-6. PMID 18772108 DOI: 10.1016/j.ccr.2008.08.006  0.36
2008 Steeg PS, Horak CE, Miller KD. Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5006-12. PMID 18698018 DOI: 10.1158/1078-0432.CCR-08-0238  0.36
2008 Wang M, Cooley B, Gao M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Synthesis of new carbon-11 labeled naphthalene-sulfonamides for PET imaging of human CCR8. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 66: 1406-13. PMID 18455923 DOI: 10.1016/j.apradiso.2008.03.010  0.36
2008 Ganguli S, Bisley JW, Roitman JD, Shadlen MN, Goldberg ME, Miller KD. One-dimensional dynamics of attention and decision making in LIP. Neuron. 58: 15-25. PMID 18400159 DOI: 10.1016/j.neuron.2008.01.038  1
2008 Sharpee TO, Miller KD, Stryker MP. On the importance of static nonlinearity in estimating spatiotemporal neural filters with natural stimuli. Journal of Neurophysiology. 99: 2496-509. PMID 18353910 DOI: 10.1152/jn.01397.2007  1
2008 Doyle DM, Miller KD. Development of new targeted therapies for breast cancer. Cancer Treatment and Research. 141: 119-34. PMID 18274086  0.36
2008 Gao M, Wang M, Miller KD, Sledge GW, Zheng QH. Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer. European Journal of Medicinal Chemistry. 43: 2211-9. PMID 18272256 DOI: 10.1016/j.ejmech.2008.01.001  0.32
2008 Doyle DM, Miller KD. Development of new targeted therapies for breast cancer. Breast Cancer (Tokyo, Japan). 15: 49-56. PMID 18224395 DOI: 10.1007/s12282-007-0003-2  0.36
2008 Gao M, Wang M, Mock BH, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Synthesis of new carbon-11 labeled cyclofenil derivatives for PET imaging of breast cancer estrogen receptors. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 66: 523-9. PMID 18155914 DOI: 10.1016/j.apradiso.2007.11.006  0.36
2008 Miller KD. Simon and Polanyi on rationality and knowledge Organization Studies. 29: 933-955. DOI: 10.1177/0170840608090532  0.32
2008 Iyer DN, Miller KD. Performance feedback, slack, and the timing of acquisitions Academy of Management Journal. 51: 808-822.  0.32
2008 Mamounas EP, Budd GT, Miller KD. Incorporating the oncotype DX breast cancer assay into community pratice: An expert Q&A and case study sampling Clinical Advances in Hematology and Oncology. 6.  0.36
2007 Shen C, Breen TE, Dobrolecki LE, Schmidt CM, Sledge GW, Miller KD, Hickey RJ. Comparison of computational algorithms for the classification of liver cancer using SELDI mass spectrometry: a case study. Cancer Informatics. 3: 329-39. PMID 19455252  0.36
2007 Salter JT, Miller KD. Antiangiogenic agents in breast cancer. Cancer Investigation. 25: 518-26. PMID 18027149 DOI: 10.1080/07357900701648516  0.36
2007 Wang M, Gao M, Miller KD, Sledge GW, Zheng QH. Synthesis of carbon-11 labeled biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues as new potential PET glioma tumor imaging agents. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 65: 1152-9. PMID 17604635 DOI: 10.1016/j.apradiso.2007.05.006  0.32
2007 Palmer SE, Miller KD. Effects of inhibitory gain and conductance fluctuations in a simple model for contrast-invariant orientation tuning in cat V1. Journal of Neurophysiology. 98: 63-78. PMID 17507506 DOI: 10.1152/jn.00152.2007  1
2007 Wang M, Lacy G, Gao M, Miller KD, Sledge GW, Zheng QH. Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer. Bioorganic & Medicinal Chemistry Letters. 17: 332-6. PMID 17095221 DOI: 10.1016/j.bmcl.2006.10.065  0.32
2007 Mina L, Soule SE, Badve S, Baehner FL, Baker J, Cronin M, Watson D, Liu ML, Sledge GW, Shak S, Miller KD. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Research and Treatment. 103: 197-208. PMID 17039265 DOI: 10.1007/s10549-006-9366-x  0.36
2007 James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Investigational New Drugs. 25: 41-8. PMID 16969706 DOI: 10.1007/s10637-006-9008-5  0.32
2007 Chen WR, Miller KD. Situational and institutional determinants of firms' R&D search intensity Strategic Management Journal. 28: 368-381. DOI: 10.1002/smj.594  0.32
2006 Wang M, Gao M, Mock BH, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents. Bioorganic & Medicinal Chemistry. 14: 8599-607. PMID 16962783 DOI: 10.1016/j.bmc.2006.08.026  0.36
2006 Gao M, Wang M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Synthesis of radiolabeled stilbene derivatives as new potential PET probes for aryl hydrocarbon receptor in cancers. Bioorganic & Medicinal Chemistry Letters. 16: 5767-72. PMID 16950622 DOI: 10.1016/j.bmcl.2006.08.088  0.36
2006 Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW, Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ. Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. The Prostate. 66: 1498-511. PMID 16921510 DOI: 10.1002/pros.20482  0.36
2006 Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW, Herbert BS. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3184-92. PMID 16707619 DOI: 10.1158/1078-0432.CCR-05-2760  0.36
2006 Wang JQ, Gao M, Miller KD, Sledge GW, Zheng QH. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 16: 4102-6. PMID 16697188 DOI: 10.1016/j.bmcl.2006.04.080  0.32
2006 Sharpee TO, Sugihara H, Kurgansky AV, Rebrik SP, Stryker MP, Miller KD. Adaptive filtering enhances information transmission in visual cortex. Nature. 439: 936-42. PMID 16495990 DOI: 10.1038/nature04519  1
2006 Miller KD, Miller M, Mehrotra S, Agarwal B, Mock BH, Zheng QH, Badve S, Hutchins GD, Sledge GW. A physiologic imaging pilot study of breast cancer treated with AZD2171. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 281-8. PMID 16397053 DOI: 10.1158/1078-0432.CCR-05-0219  0.36
2005 Wang JQ, Miller KD, Sledge GW, Zheng QH. Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 15: 4380-4. PMID 16019210 DOI: 10.1016/j.bmcl.2005.06.038  0.32
2005 Gao M, Miller KD, Sledge GW, Zheng QH. Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers. Bioorganic & Medicinal Chemistry Letters. 15: 3865-9. PMID 15993064 DOI: 10.1016/j.bmcl.2005.05.108  0.32
2005 Schneider BP, Miller KD. Angiogenesis of breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 1782-90. PMID 15755986 DOI: 10.1200/JCO.2005.12.017  0.36
2005 Miller KD, Soule SE, Calley C, Emerson RE, Hutchins GD, Kopecky K, Badve S, Storniolo A, Goulet R, Sledge GW. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment. 89: 187-97. PMID 15692762 DOI: 10.1007/s10549-004-2044-y  0.36
2005 Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 792-9. PMID 15681523 DOI: 10.1200/JCO.2005.05.098  0.36
2005 Miller KD, Sweeney CJ, Sledge GW. Can tumor angiogenesis be inhibited without resistance? Exs. 95-112. PMID 15617473  0.36
2004 Sharpee T, Sugihara H, Kurgansky AV, Rebrik S, Stryker MP, Miller KD. Probing feature selectivity of neurons in primary visual cortex with natural stimuli. Proceedings of Spie--the International Society For Optical Engineering. 212-222. PMID 18633451 DOI: 10.1117/12.548513  1
2004 Fei X, Wang JQ, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nuclear Medicine and Biology. 31: 1033-41. PMID 15607485 DOI: 10.1016/j.nucmedbio.2004.02.006  0.36
2004 Miller KD, Dul CL. Breast cancer: the role of angiogenesis and antiangiogenic therapy. Hematology/Oncology Clinics of North America. 18: 1071-86, ix. PMID 15474336 DOI: 10.1016/j.hoc.2004.06.010  0.36
2004 Miller KD. The role of ErbB inhibitors in trastuzumab resistance. The Oncologist. 9: 16-9. PMID 15163843  0.36
2004 Miller KD. Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? Breast Cancer Research : Bcr. 6: 128-32. PMID 15084233 DOI: 10.1186/bcr782  0.36
2004 Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 1971-5. PMID 15041714  0.32
2004 Emondi AA, Rebrik SP, Kurgansky AV, Miller KD. Tracking neurons recorded from tetrodes across time. Journal of Neuroscience Methods. 135: 95-105. PMID 15020094 DOI: 10.1016/j.jneumeth.2003.12.022  1
2004 Fei X, Zheng QH, Wang JQ, Stone KL, Martinez TD, Miller KD, Sledge GW, Hutchins GD. Synthesis, biodistribution and micro-PET imaging of radiolabeled antimitotic agent T138067 analogues. Bioorganic & Medicinal Chemistry Letters. 14: 1247-51. PMID 14980675 DOI: 10.1016/j.bmcl.2003.12.061  0.36
2004 Zheng QH, Fei X, Liu X, Wang JQ, Stone KL, Martinez TD, Gay DJ, Baity WL, Miller KD, Sledge GW, Hutchins GD. Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4'-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide. Nuclear Medicine and Biology. 31: 77-85. PMID 14741572 DOI: 10.1016/S0969-8051(03)00111-2  0.36
2004 Miller KD, Soule SE, Haney LG, Guiney P, Murry DJ, Lenaz L, Sun SL, Sledge GW. A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer. Investigational New Drugs. 22: 69-73. PMID 14707496  0.32
2004 Lauritzen TZ, Miller KD. The contributions of inhibition and noise to responses in V1 Neurocomputing. 58: 901-907. DOI: 10.1016/j.neucom.2004.01.144  1
2004 Miller KD, Arikan AT. Technology search investments: Evolutionary, option reasoning, and option pricing approaches Strategic Management Journal. 25: 473-485. DOI: 10.1002/smj.392  0.32
2004 Miller KD, Shapira Z. An empirical test of heuristics and biases affecting real option valuation Strategic Management Journal. 25: 269-284.  0.32
2004 Miller KD, Chen WR. Variable organizational risk preferences: Tests of the March-Shapira model Academy of Management Journal. 47: 105-115.  0.32
2003 Liu RC, Miller KD, Merzenich MM, Schreiner CE. Acoustic variability and distinguishability among mouse ultrasound vocalizations. The Journal of the Acoustical Society of America. 114: 3412-22. PMID 14714820 DOI: 10.1121/1.1623787  1
2003 Lauritzen TZ, Miller KD. Different roles for simple-cell and complex-cell inhibition in V1. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 10201-13. PMID 14614078  1
2003 Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Seminars in Oncology. 30: 117-24. PMID 14613032  0.36
2003 Murphy BK, Miller KD. Multiplicative gain changes are induced by excitation or inhibition alone. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 10040-51. PMID 14602818  1
2003 Zheng QH, Fei X, DeGrado TR, Wang JQ, Stone KL, Martinez TD, Gay DJ, Baity WL, Mock BH, Glick-Wilson BE, Sullivan ML, Miller KD, Sledge GW, Hutchins GD. Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester. Nuclear Medicine and Biology. 30: 753-60. PMID 14499334 DOI: 10.1016/S0969-8051(03)00086-6  0.36
2003 Kruger RA, Kiser WL, Reinecke DR, Kruger GA, Miller KD. Thermoacoustic molecular imaging of small animals. Molecular Imaging. 2: 113-23. PMID 12964308 DOI: 10.1162/153535003322331993  0.36
2003 Sledge GW, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. European Journal of Cancer (Oxford, England : 1990). 39: 1668-75. PMID 12888360 DOI: 10.1016/S0959-8049(03)00273-9  0.36
2003 Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, Sledge GW. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 14: 1072-7. PMID 12853349  0.32
2003 Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Research. 63: 3425-9. PMID 12810680  0.36
2003 Fei X, Zheng QH, Liu X, Wang JQ, Sun HB, Mock BH, Stone KL, Miller KD, Sledge GW, Hutchins GD. Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. Bioorganic & Medicinal Chemistry Letters. 13: 2217-22. PMID 12798337 DOI: 10.1016/S0960-894X(03)00382-2  0.36
2003 Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. The Journal of Biological Chemistry. 278: 21631-8. PMID 12690099 DOI: 10.1074/jbc.M300609200  0.36
2003 Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clinical Breast Cancer. 3: 421-2. PMID 12636887 DOI: 10.3816/CBC.2003.n.007  0.36
2003 Sweeney CJ, Miller KD, Sledge GW. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends in Molecular Medicine. 9: 24-9. PMID 12524207 DOI: 10.1016/S1471-4914(02)00007-2  0.36
2003 Miller KD, Sweeney CJ, Sledge GW. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 14: 20-8. PMID 12488288  0.32
2003 Miller KD. Understanding layer 4 of the cortical circuit: a model based on cat V1. Cerebral Cortex (New York, N.Y. : 1991). 13: 73-82. PMID 12466218  1
2003 Miller KD, Waller HG. Scenarios, real options and integrated risk management Long Range Planning. 36: 93-107. DOI: 10.1016/S0024-6301(02)00205-4  0.32
2003 Eisele M, Miller KD. Hidden Markov model of cortical synaptic plasticity: Derivation of the learning rule Advances in Neural Information Processing Systems 1
2002 Zheng QH, Stone KL, Mock BH, Miller KD, Fei X, Liu X, Wang JQ, Glick-Wilson BE, Sledge GW, Hutchins GD. [11C]Choline as a potential PET marker for imaging of breast cancer athymic mice. Nuclear Medicine and Biology. 29: 803-7. PMID 12453589 DOI: 10.1016/S0969-8051(02)00339-6  0.36
2002 Zheng QH, Fei X, Liu X, Wang JQ, Bin Sun H, Mock BH, Lee Stone K, Martinez TD, Miller KD, Sledge GW, Hutchins GD. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nuclear Medicine and Biology. 29: 761-70. PMID 12381456 DOI: 10.1016/S0969-8051(02)00338-4  0.36
2002 Soule SE, Miller KD, Porcu P, Ansari R, Fata F, McClean JW, Zon R, Sledge GW, Einhorn LH. Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 13: 1612-5. PMID 12377650 DOI: 10.1093/annonc/mdf283  0.36
2002 Miller KD. Issues and challenges for antiangiogenic therapies. Breast Cancer Research and Treatment. 75: S45-50; discussion S. PMID 12353823  0.36
2002 Miller KD, Gradishar W, Schuchter L, Sparano JA, Cobleigh M, Robert N, Rasmussen H, Sledge GW. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 13: 1220-4. PMID 12181245  0.32
2002 Troyer TW, Krukowski AE, Miller KD. LGN input to simple cells and contrast-invariant orientation tuning: an analysis. Journal of Neurophysiology. 87: 2741-52. PMID 12037176  1
2002 Sledge GW, Miller KD. Angiogenesis and antiangiogenic therapy. Current Problems in Cancer. 26: 1-60. PMID 11961506 DOI: 10.1067/mcn.2002.122105  0.36
2002 Miller KD, Troyer TW. Neural noise can explain expansive, power-law nonlinearities in neural response functions. Journal of Neurophysiology. 87: 653-9. PMID 11826034  1
2002 Kayser AS, Miller KD. Opponent inhibition: a developmental model of layer 4 of the neocortical circuit. Neuron. 33: 131-42. PMID 11779486 DOI: 10.1016/S0896-6273(01)00570-0  1
2002 Lauritzen TZ, Miller KD. Local correlation-based ("push-pull") circuitry can account for non-linear summation of stimuli in a model of cat VI Neurocomputing. 44: 509-513. DOI: 10.1016/S0925-2312(02)00409-5  1
2002 Miller KD. Knowledge inventories and managerial myopia Strategic Management Journal. 23: 689-706. DOI: 10.1002/smj.245  0.32
2002 Miller KD, Folta TB. Research notes and commentaries option value and entry timing Strategic Management Journal. 23: 655-665. DOI: 10.1002/smj.244  0.32
2002 Miller KD. Competitive strategies of religious organizations Strategic Management Journal. 23: 435-456. DOI: 10.1002/smj.234  0.32
2002 Folta TB, Miller KD. Real options in equity partnerships Strategic Management Journal. 23: 77-88. DOI: 10.1002/smj.209  0.32
2001 Miller KD, Rahman ZU, Sledge GW. Selection bias in clinical trials. Breast Disease. 14: 31-40. PMID 15687634  0.32
2001 Miller KD, Erwin E. Effects of monocular deprivation and reverse suture on orientation maps can be explained by activity-instructed development of geniculocortical connections. Visual Neuroscience. 18: 821-34. PMID 11925017 DOI: 10.1017/S0952523801185159  1
2001 Liu RC, Tzonev S, Rebrik S, Miller KD. Variability and information in a neural code of the cat lateral geniculate nucleus. Journal of Neurophysiology. 86: 2789-806. PMID 11731537  1
2001 Lauritzen TZ, Krukowski AE, Miller KD. Local correlation-based circuitry can account for responses to multi-grating stimuli in a model of cat V1. Journal of Neurophysiology. 86: 1803-15. PMID 11600641  1
2001 Soule SE, Miller KD. Adjuvant chemotherapy for tumors of one centimeter or less: the law of diminishing returns. Current Oncology Reports. 3: 529-35. PMID 11595122  0.36
2001 Miller KD, Pinto DJ, Simons DJ. Processing in layer 4 of the neocortical circuit: new insights from visual and somatosensory cortex. Current Opinion in Neurobiology. 11: 488-97. PMID 11502397 DOI: 10.1016/S0959-4388(00)00239-7  1
2001 Kayser A, Priebe NJ, Miller KD. Contrast-dependent nonlinearities arise locally in a model of contrast-invariant orientation tuning. Journal of Neurophysiology. 85: 2130-49. PMID 11353028  1
2001 Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Research. 61: 3369-72. PMID 11309294  0.32
2001 Krukowski AE, Miller KD. Thalamocortical NMDA conductances and intracortical inhibition can explain cortical temporal tuning. Nature Neuroscience. 4: 424-30. PMID 11276234 DOI: 10.1038/86084  1
2001 Miller KD, Sisk J, Ansari R, Gize G, Nattam S, Pennington K, Monaco F, Sledge GW. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Williston Park, N.Y.). 15: 38-40. PMID 11252888  0.36
2001 Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 1195-206. PMID 11181686  0.32
2001 Krukowski A, Miller K. Orientation response properties of inhibitory cells in a model of cat primary visual cortex Journal of Vision. 1: 434a. DOI: 10.1167/1.3.434  1
2001 Miller KD, Kayser AS. A model for the development of V1 columnar circuitry Journal of Vision. 1: 199a. DOI: 10.1167/1.3.199  1
2001 Krukowski AE, Troyer TW, Miller KD. A model of visual cortical temporal frequency tuning Neurocomputing. 38: 1379-1383. DOI: 10.1016/S0925-2312(01)00499-4  1
2001 Lauritzen TZ, Krukowski AE, Miller KD. A model of cross-orientation inhibition in cat primary visual cortex Neurocomputing. 38: 757-762. DOI: 10.1016/S0925-2312(01)00427-1  1
2000 Miller KD, Sledge GW. High-dose chemotherapy in breast cancer -- the perils of history uncontrolled. Medscape Women's Health. 5: E1. PMID 11109042  0.36
2000 Miller KD, Michael H, Jacobson L, Sutton GP. Primary yolk sac tumor of the rectum. Cancer Investigation. 18: 597-601. PMID 11036466  0.36
2000 Song S, Miller KD, Abbott LF. Competitive Hebbian learning through spike-timing-dependent synaptic plasticity. Nature Neuroscience. 3: 919-26. PMID 10966623 DOI: 10.1038/78829  1
2000 Kruger RA, Miller KD, Reynolds HE, Kiser WL, Reinecke DR, Kruger GA. Breast cancer in vivo: contrast enhancement with thermoacoustic CT at 434 MHz-feasibility study. Radiology. 216: 279-83. PMID 10887262 DOI: 10.1148/radiology.216.1.r00jl30279  0.36
2000 Ferster D, Miller KD. Neural mechanisms of orientation selectivity in the visual cortex. Annual Review of Neuroscience. 23: 441-71. PMID 10845071 DOI: 10.1146/annurev.neuro.23.1.441  1
2000 Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, Swan D, Krupp KR, Miller KD, Novotny PJ. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 1068-74. PMID 10694559  0.36
1999 Miller KD, Sledge GW. Toward checkmate: biology and breast cancer therapy for the new millennium. Investigational New Drugs. 17: 417-27. PMID 10759407 DOI: 10.1023/A:1006311227965  0.36
1999 Bush PC, Prince DA, Miller KD. Increased pyramidal excitability and NMDA conductance can explain posttraumatic epileptogenesis without disinhibition: a model. Journal of Neurophysiology. 82: 1748-58. PMID 10515964  1
1999 Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, Sledge GW. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 3033-7. PMID 10506597  0.32
1999 Miller KD, Erwin E, Kayser A. Is the development of orientation selectivity instructed by activity? Journal of Neurobiology. 41: 44-57. PMID 10504191 DOI: 10.1002/(SICI)1097-4695(199910)41:1<44::AID-NEU7>3.0.CO;2-V  1
1999 Erwin E, Miller KD. The subregion correspondence model of binocular simple cells. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 7212-29. PMID 10436074  1
1999 Miller KD, Sledge GW. The role of chemotherapy for metastatic breast cancer. Hematology/Oncology Clinics of North America. 13: 415-34. PMID 10363138 DOI: 10.1016/S0889-8588(05)70063-0  0.36
1999 Sledge GW, Miller KD. Metastatic breast cancer: the role of chemotherapy. Seminars in Oncology. 26: 6-10. PMID 10190779  0.36
1999 Miller KD, Sledge GW. Taxanes in the treatment of breast cancer: a prodigy comes of age. Cancer Investigation. 17: 121-36. PMID 10071597  0.36
1999 Rebrik SP, Wright BD, Emondi AA, Miller KD. Cross-channel correlations in tetrode recordings: Implications for spike-sorting Neurocomputing. 26: 1033-1038. DOI: 10.1016/S0925-2312(99)00101-0  1
1998 Erwin E, Miller KD. Correlation-based development of ocularly matched orientation and ocular dominance maps: determination of required input activities. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 9870-95. PMID 9822745  1
1998 Troyer TW, Krukowski AE, Priebe NJ, Miller KD. Contrast-invariant orientation tuning in cat visual cortex: thalamocortical input tuning and correlation-based intracortical connectivity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 5908-27. PMID 9671678  1
1998 Miller KD. Equivalence of a sprouting-and-retraction model and correlation-based plasticity models of neural development. Neural Computation. 10: 529-47. PMID 9527832  1
1998 Miller KD. Economic Exposure and Integrated Risk Management Strategic Management Journal. 19: 497-514.  0.32
1998 Miller KD, Reuer JJ. Asymmetric corporate exposures to foreign exchange rate changes Strategic Management Journal. 19: 1183-1191.  0.32
1998 Miller KD, Reuer JJ. Firm strategy and economic exposure to foreign exchange rate Movements Journal of International Business Studies. 29: 493-514.  0.32
1997 Wimbauer S, Wenisch OG, van Hemmen JL, Miller KD. Development of spatiotemporal receptive fields of simple cells: II. Simulation and analysis. Biological Cybernetics. 77: 463-77. PMID 9433757  1
1997 Wimbauer S, Wenisch OG, Miller KD, van Hemmen JL. Development of spatiotemporal receptive fields of simple cells: I. Model formulation. Biological Cybernetics. 77: 453-61. PMID 9433756  1
1997 Miller KD, Loehrer PJ, Gonin R, Einhorn LH. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 1427-31. PMID 9193335  0.36
1997 Troyer TW, Miller KD. Physiological gain leads to high ISI variability in a simple model of a cortical regular spiking cell. Neural Computation. 9: 971-83. PMID 9188190  1
1997 Reuer JJ, Miller KD. Agency costs and the performance implications of international joint venture internalization Strategic Management Journal. 18: 425-438.  0.32
1996 Miller KD, Loehrer PJ, Gonin R, Weber G, Ansari R, Pletcher W, McClean J, Spiridonidis CH, Mortimer J. A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma. Investigational New Drugs. 14: 207-12. PMID 8913842  0.36
1996 Miller KD. Synaptic economics: competition and cooperation in synaptic plasticity. Neuron. 17: 371-4. PMID 8816700 DOI: 10.1016/S0896-6273(00)80169-5  1
1996 Miller KD, Leiblein MJ. Corporate risk-return relations: Returns variability versus downside risk Academy of Management Journal. 39: 91-122.  0.32
1996 Miller KD, Reuer JJ. Measuring organizational downside risk Strategic Management Journal. 17: 671-691.  0.32
1994 Miller KD. A model for the development of simple cell receptive fields and the ordered arrangement of orientation columns through activity-dependent competition between ON- and OFF-center inputs. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 14: 409-41. PMID 8283248  1
1994 Miller KD. Models of activity-dependent neural development. Progress in Brain Research. 102: 303-18. PMID 7800821 DOI: 10.1016/S0079-6123(08)60548-8  1
1993 Lin PP, Allison DC, Wainstock J, Miller KD, Dooley WC, Friedman N, Baker RR. Impact of axillary lymph node dissection on the therapy of breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 1536-44. PMID 8336192  0.36
1992 Miller KD. Development of orientation columns via competition between ON- and OFF-center inputs. Neuroreport. 3: 73-6. PMID 1611038  1
1992 Miller KD. Introduction: The use of models in the neurosciences Seminars in Neuroscience. 4: 1-3. DOI: 10.1016/1044-5765(92)90028-Z  1
1990 Stryker MP, Chapman B, Miller KD, Zahs KR. Experimental and theoretical studies of the organization of afferents to single orientation columns in visual cortex. Cold Spring Harbor Symposia On Quantitative Biology. 55: 515-27. PMID 2132835  1
1990 Mayer DC, Lee A, Kramer AR, Miller KD. High-Performance CMOS/SOS Circuits in SPEAR<sup>TM</sup> Material Ieee Journal of Solid-State Circuits. 25: 318-321. DOI: 10.1109/4.50322  0.36
1990 Mackay DJC, Miller KD. Analysis of linsker's application of hebbian rules to linear networks Network: Computation in Neural Systems. 1: 257-297. DOI: 10.1088/0954-898X_1_3_001  1
1989 Miller KD, Keller JB, Stryker MP. Ocular dominance column development: analysis and simulation. Science (New York, N.Y.). 245: 605-15. PMID 2762813  1
1989 Miller KD, Chapman B, Stryker MP. Visual responses in adult cat visual cortex depend on N-methyl-D-aspartate receptors. Proceedings of the National Academy of Sciences of the United States of America. 86: 5183-7. PMID 2567996  1
1988 Miller KD, Stryker MP, Keller JB. Network model of ocular dominance column formation: Computational results Neural Networks. 1: 267. DOI: 10.1016/0893-6080(88)90301-2  1
1988 Miller KD, Keller JB, Stryker MP. Network model of ocular dominance column formation: Analytical results Neural Networks. 1: 266. DOI: 10.1016/0893-6080(88)90300-0  1
Show low-probability matches.